Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
RESEARCH TOOLSreports
Holding DNTH?
Track your performance easily
DNTH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.58 - $33.77
Previous Close$20.27
Volume283.43K
Average Volume (3M)245.26K
Market Cap
$599.93M
Enterprise Value$319.12M
Total Cash (Recent Filing)$281.12M
Total Debt (Recent Filing)$311.00K
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Mar 20, 2025EPS Estimate
-$0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.50
Shares Outstanding29,596,965
10 Day Avg. Volume466,044
30 Day Avg. Volume245,265
Standard Deviation0.23
R-Squared0.17
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.82
Price to Sales (P/S)122.83
Price to Cash Flow (P/CF)-7.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue138.75
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.39
Forecast
1Y Price Target
$48.75Price Target Upside118.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Dianthus Therapeutics News
PremiumCompany Announcements
Dianthus Therapeutics Reports Q3 Progress and Financials
PremiumCompany Announcements
Dianthus Therapeutics Appoints Steven Romano to Board
Bulls Say, Bears Say
Bulls Say
Financial PerformanceDianthus reported license revenue of $2.2M, which exceeded the consensus estimate of $0.7M.
Market OpportunityPotential total market opportunity for DNTH103 is approaching $20 billion, with generalized myasthenia gravis alone expected to have a $12 billion total addressable market by 2030.
Product DifferentiationDNTH103 will be meaningfully differentiated from other complement inhibitors for gMG due to the expectation that it will not have a black box warning, as well as the convenient anticipated dosing of one SQ autoinjector injection every two weeks.
Bears Say
Financial PerformanceThe company reported a net loss of $25 million, which is a significant increase from the previous quarter's $18 million loss, largely due to rising research and development expenses.
Product AdministrationAdministration of Uplizna requires screening for Hepatitis B and tuberculosis, as well as premedication before each infusion, which could complicate its use.
Product ConcernsThere are unresolved questions about the long-term safety and effectiveness of Uplizna, particularly regarding the impact of B-cell depletion.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DNTH FAQ
What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was $6.58 and its highest was $33.77 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Currently, no data Available
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s upcoming earnings report date is Mar 20, 2025 which is in 117 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.595 by -$0.145.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate is -$0.85.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 29,596,966 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.595. Following the earnings report the stock price went down -2.809%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Among the largest hedge funds holding Dianthus Therapeutics’s share is Fairmount Funds Management Llc. It holds Dianthus Therapeutics’s shares valued at 74M.
---
Dianthus Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.75 (118.22% Upside)
$48.75 (118.22% Upside)
Blogger Sentiment
Bullish
DNTH Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 62.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.6%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
76.26%
12-Months-Change
Fundamentals
Return on Equity
-25.99%
Trailing 12-Months
Asset Growth
84.06%
Trailing 12-Months
Company Description
Dianthus Therapeutics
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.
---
DNTH Stock 12 Month Forecast
Average Price Target
$48.75
▲(118.22% Upside)
Technical Analysis
ALX Oncology Holdings
―
Arcutis Biotherapeutics
―
Black Diamond Therapeutics
―
Cabaletta Bio
―
Best Analysts Covering DNTH
1 Year
1 Year Success Rate
2/6 ratings generated profit
1 Year Average Return
+3.67%
reiterated a buy rating 4 months ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +3.67% per trade.
---